Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 권기환 | * |
dc.date.accessioned | 2023-10-19T16:31:12Z | - |
dc.date.available | 2023-10-19T16:31:12Z | - |
dc.date.issued | 2023 | * |
dc.identifier.issn | 1226-3303 | * |
dc.identifier.other | OAK-34160 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/266257 | - |
dc.description.abstract | Background/Aims: The Genoss DES™ is a novel, biodegradable, polymer-coated, sirolimus-eluting stent with a cobalt-chromium stent platform and thin strut. Although the safety and effectiveness of this stent have been previously investigated, real-world clinical outcomes data are lacking. Therefore, the aim of this prospective, multicenter trial was to evaluate the clinical safety and effectiveness of the Genoss DES™ in all-comer patients undergoing percutaneous coronary intervention. Methods: The Genoss DES registry is a prospective, single-arm, observational trial for evaluation of clinical outcomes after Genoss DES™ implantation in all-comer patients undergoing percutaneous coronary intervention from 17 sites in South Korea. The primary endpoint was a device-oriented composite outcome of cardiac death, target vessel-related myocardial infarction (MI), and clinically driven target lesion revascularization (TLR) at 12 months. Results: A total of 1,999 patients (66.4 ± 11.1 years of age; 72.8% male) were analyzed. At baseline, 62.8% and 36.7% of patients had hypertension and diabetes, respectively. The implanted stent number, diameter, and length per patient were 1.5 ± 0.8, 3.1 ± 0.5 mm, and 37.0 ± 25.0 mm, respectively. The primary endpoint occurred in 1.8% patients, with a cardiac death rate of 1.1%, target vessel-related MI rate of 0.2%, and clinically driven TLR rate of 0.8%. Conclusions: In this real-world registry, the Genoss DES™ demonstrated excellent safety and effectiveness at 12 months among all-comer patients undergoing percutaneous coronary intervention. These findings suggest that the Genoss DES™ may be a viable treatment option for patients with coronary artery disease. © 2023 The Korean Association of Internal Medicine. | * |
dc.language | English | * |
dc.publisher | Korean Association of Internal Medicine | * |
dc.subject | Drug-eluting stents | * |
dc.subject | Percutaneous coronary intervention | * |
dc.subject | Prospective studies | * |
dc.subject | Registries | * |
dc.title | Clinical safety and effectiveness of the Genoss drug-eluting stent in real-world clinical practice | * |
dc.type | Article | * |
dc.relation.issue | 5 | * |
dc.relation.volume | 38 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.index | KCI | * |
dc.relation.startpage | 683 | * |
dc.relation.lastpage | 691 | * |
dc.relation.journaltitle | Korean Journal of Internal Medicine | * |
dc.identifier.doi | 10.3904/kjim.2023.129 | * |
dc.identifier.scopusid | 2-s2.0-85170294121 | * |
dc.author.google | Youn Y.J. | * |
dc.author.google | Lee J.-W. | * |
dc.author.google | Ahn S.G. | * |
dc.author.google | Lee S.-H. | * |
dc.author.google | Yoon J. | * |
dc.author.google | Park J.H. | * |
dc.author.google | Yoo S.-Y. | * |
dc.author.google | Kang W.C. | * |
dc.author.google | Lee N.H. | * |
dc.author.google | Kwon K.H. | * |
dc.author.google | Doh J.H. | * |
dc.author.google | Lim S.-W. | * |
dc.author.google | Jang Y.S. | * |
dc.author.google | Jeon D.W. | * |
dc.author.google | Heo J.H. | * |
dc.author.google | Choi W.G. | * |
dc.author.google | Cho S. | * |
dc.author.google | Lee B.-K. | * |
dc.author.google | Jeong H. | * |
dc.author.google | Hong B.-K. | * |
dc.author.google | Choi H.-H. | * |
dc.contributor.scopusid | 권기환(57203037966) | * |
dc.date.modifydate | 20240118164632 | * |